FX and R&D lower FY18 outlook
16/03/18 -"Following the Q4 17 trading update, bioMerieux released its FY17 results which were largely in line with our estimates. On sales growth of 8.8% (+10.2% at CER; c.2x market growth), the adjusted ..."
Pages
62
Language
English
Published on
16/03/18
You may also be interested by these reports :
22/03/24
We have included the announced 1,000-to-1 reverse stock split into our number of shares, following the effectiveness of the share consolidation and ...
22/03/24
We have maintained our assumption and the company’s plan of a €300m capital increase to be completed in 2024, but with an expected subscription price ...
21/03/24
Bastide’s half-year turnover and EBITDA both saw decent yoy growth despite heavier payroll costs, while the underlying operating margin moderately ...
18/03/24
DiaSorin’s 2023 results were in line with street expectations, however the profitability guidance miss disappointed investors. Healthy performance by ...